Proacta

company

About

Proacta is a clinical-stage biopharmaceutical company developing hypoxia-activated “prodrugs” for the treatment of cancer.

  • 1 - 10

Details

Last Funding Type
Series B
Last Funding Money Raised
$35M
Industries
Biotechnology,Health Care,Medical Device
Founded date
Jan 1, 2004
Number Of Employee
1 - 10
Operating Status
Active

Proacta Inc. is a private, clinical-stage, biopharmaceutical company headquartered in San Diego, California. They are focused on addressing unmet needs in the field of cancer with the development of hypoxia-activated prodrugs that target cancer cells.

Proacta was founded on intellectual property generated in New Zealand at the University of Auckland and in the United States at Stanford University.

Proacta's patent family covers a series of hypoxia-activated prodrugs designed to treat cancer. Expansion of this portfolio is supported by ongoing research at The University of Auckland.

PR610 is the lead compound from their pipeline of pro-drugs based on hypoxia-activated tyrosine-kinase inhibitors. These pro-drugs selectively release active tyrosine-kinase inhibitors within the low-oxygen (hypoxic) environment found in many solid tumors. By shifting the release of active drug away from normal tissues and into cancer tissues, these drugs are predicted to be more effective and less toxic than currently available therapies.

To date, Proacta has raised $43 million in two private financings. Investors include Alta Partners, Clarus Ventures, Delphi Ventures, Endeavour Capital (New Zealand), GBS Venture Partners (Australia), Genentech, No 8 Ventures (New Zealand) and Roche.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
3
$43.50M
Proacta has raised a total of $43.50M in funding over 2 rounds. Their latest funding was raised on Feb 7, 2007 from a Series B round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Feb 7, 2007 Series B $35M 1 Detail
Sep 11, 2006 Series A $7M 1 Detail
Jul 26, 2004 Series A $1.50M 1 Detail

Investors

Number of Lead Investors
Number of Investors
1
Proacta is funded by 1 investors. Roche are the most recent investors.
Investor Name Lead Investor Funding Round
Roche Series B